FIGURE 2 from Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

Abstract

<p><i>ALK</i> resistance mutations observed in clinical (<i>n</i> = 26; <b>A</b>) and liquid biopsy (<i>n</i> = 202; <b>B</b>) cohorts, by patient (columns) and grouped by <i>EML4-ALK</i> variant type. Filled regions of the oncoprint indicate presence of the <i>ALK</i> resistance mutation designated by the row name for a given patient. Resistance mutation percentages indicate share of each among total patients, by cohort. Both G1202R and I1171N are associated with <i>EML4-ALK</i> v3 and L1196M is associated with <i>EML4-ALK</i> non-v3.</p>